Menu
Search
|

Menu

Close
X

Genetic Technologies Ltd GENE.OQ (NASDAQ Stock Exchange Capital Market)

1.16 USD
+0.02 (+1.75%)
As of 3:59 PM EST
chart
Previous Close 1.14
Open 1.14
Volume 690
3m Avg Volume 64,515
Today’s High 1.16
Today’s Low 1.13
52 Week High 2.05
52 Week Low 0.79
Shares Outstanding (mil) 17.63
Market Capitalization (mil) 18.96
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, AUD)
FY18
0
FY17
1
FY16
1
FY15
2
EPS (AUD)
FY18
-0.002
FY17
-0.004
FY16
-0.005
FY15
-0.010
*Note: Units in Millions of Australian Dollars
**Note: Units in Australian Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.53
Price to Sales (TTM)
vs sector
138.84
22.95
Price to Book (MRQ)
vs sector
5.73
4.15
Price to Cash Flow (TTM)
vs sector
--
20.94
Total Debt to Equity (MRQ)
vs sector
0.00
15.47
LT Debt to Equity (MRQ)
vs sector
0.00
11.13
Return on Investment (TTM)
vs sector
-71.15
13.00
Return on Equity (TTM)
vs sector
-71.47
14.69

EXECUTIVE LEADERSHIP

Paul Kasian
Non-Executive Chairman of the Board, Acting Chief Executive Officer, Since 2018
Salary: --
Bonus: --
Kevin Fischer
Chief Financial Officer, Company Secretary, Since 2016
Salary: --
Bonus: --
Mark Ostrowski
President of Phenogen Sciences Inc, Since 2014
Salary: $221,953.00
Bonus: --
Richard Allman
Scientific Director, Since 2012
Salary: $114,076.00
Bonus: --
M. Luisa Ashdown
Director of Global Licensing and Intellectual Property, Since 2012
Salary: $141,440.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

60-66 Hanover Street
Fitzroy   VIC   3065

Phone: +613.94151135

Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women's health. The Company's lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The Company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/gynecologists (OBGYNs) and breast cancer risk assessment specialists, such as breast surgeons. The Company operates in Australia, the United States and Switzerland. The Company's subsidiaries include Genetic Technologies Corporation Pty. Ltd. and Phenogen Sciences Inc. Genetic Technologies Corporation Pty. Ltd. is engaged in genetic testing. The Company has launched the BREVAGen test across the United States through Phenogen Sciences Inc.

SPONSORED STORIES